Publications & posters Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts. Filter View all EFX FGF21 NASH Nov 2014 | FROM EXTERNAL EXPERTS Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets Fisher, F.M. et al. Gastroenterology Nov 2009 | FROM EXTERNAL EXPERTS Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models–association with liver and adipose tissue effects Xu, J. et al. American Journal of Physiology. Endocrinology and Metabolism Feb 2007 | FROM EXTERNAL EXPERTS The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21 Kharitonenkov, A. et al. Endocrinology Page 5 of 5<<12345 We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline. View Our Pipeline We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline. View Our Pipeline